NEW YORK – Veracyte on Wednesday announced a collaboration with Paris-based cancer center Gustave Roussy to study the biology of metastatic tumors to better inform precision cancer drug development.
Veracyte will use the machine learning and multiomics testing capabilities within its Biopharma Atlas platform to analyze metastatic tumor samples and associated data in multiple cancer indications from Gustave Roussy's biorepository. The company will draw on samples from research projects conducted at Gustave Roussy's Department of Therapeutic Innovation and Early Clinical Trials and focus particularly on evaluating samples from studies where patients received new immunotherapies.
Veracyte, based in South San Francisco, California, will use the Biopharma Atlas platform to characterize each tumor's biology, particularly the tumor immune microenvironment, to garner insights into which tumors are more likely to respond to a particular therapy. Toward that end, the firm will create a reference database of genomic and immunomic biomarkers within its Biopharma Atlas that could help Veracyte's pharma partners accelerate the development of precision medicines, Corinne Danan, general manager of Veracyte's biopharma business unit, said in a statement.
"We believe that by better understanding the underlying biology of tumors, we can ultimately help improve the success rate of clinical trials for novel therapies and ensure that more patients can benefit from them once they are broadly available," Stéphane Champiat, an oncologist in Gustave Roussy's drug development department, added in a statement.